Recently, a clinical study to evaluate the safety and efficacy of pembrolizumab when administered in combination with azacitidine in NPM1-mutated AML patients with molecular relapse was recruiting (NCT03769532, Table 1). This evidence concerns the gene NPM1 and acute myeloid leukemia.